MOUNTAIN VIEW, Calif., May 15 /PRNewswire-FirstCall/ -- Alexza
Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that Carlos A. Parra
has joined the company as Vice President, Quality. He will have
responsibilities in the development and execution of quality program
strategies for Alexza's manufacturing operations and preclinical / clinical
product candidates. Mr. Parra was most recently Vice President, Operations
and Quality at Telik, Inc. in Palo Alto, California, where he was employed
since June 2002 and was responsible for all aspects of GxP pharmaceutical
development and quality operations, including manufacturing development and
GCP compliance.
Prior to his tenure at Telik, Mr. Parra was a Principal Partner at West
Coast Associates from January 1996 to June 2002. Before founding West Coast
Associates, his quality experience spanned 20 years with both small and
large pharmaceutical and biotechnology companies. Mr. Parra holds a
Bachelor's of Science in Microbiology with a minor in Engineering from the
University of Texas at El Paso.
"We are very pleased to welcome Carlos to Alexza to lead our Quality
Departments and as a member of our Management Team," said Thomas B. King,
Alexza President and CEO. "The continued rapid growth of our clinical and
preclinical programs at Alexza requires us to add integrated GLP and GCP
quality systems and procedures to our existing GMP program. Carlos brings a
wealth of U.S. and international quality expertise to Alexza, and we look
forward to his contributions to our future development."
About Alexza Pharmaceuticals
Alexza Pharmaceuticals is an emerging specialty pharmaceutical company
focused on the development and commercialization of novel, proprietary
products for the treatment of acute and intermittent conditions. The
Company's technology, the Staccato(R) system, vaporizes unformulated drug
to form a condensation aerosol that allows rapid systemic drug delivery
through deep lung inhalation. The drug is quickly absorbed through the
lungs into the bloodstream, providing speed of therapeutic onset that is
comparable to intravenous administration, but with greater ease, patient
comfort and convenience.
Alexza has six product candidates in clinical development. Alexza's
lead program, AZ-004 (Staccato loxapine) for the treatment of acute
agitation in schizophrenic or bipolar disorder patients, is in Phase 3
testing. AZ-001 (Staccato prochlorperazine) for the acute treatment of
migraine headaches has completed Phase 2 testing. AZ-104 (Staccato
loxapine) for the acute treatment of migraine headaches and AZ-002
(Staccato alprazolam) for the acute treatment of panic attacks associated
with panic disorder are in Phase 2 testing. Product candidates in Phase 1
testing include AZ-003 (Staccato fentanyl) for the treatment of
breakthrough pain, which is partnered with Endo Pharmaceuticals in North
America, and AZ-007 (Staccato zaleplon) for the treatment of insomnia. More
information, including this and past press releases from Alexza is
available online at http://www.alexza.com.
SOURCE Alexza Pharmaceuticals, Inc.
 back to top
Related links:
http://www.alexza.com
CONTACT:
Thomas B. King, President & CEO of Alexza
Pharmaceuticals, Inc., +1-650-944-7634, tking@alexza.com
|
